Delivery Order SPE2DB20D3103-SPE2DB25FP5N2
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $23,559.45 to AmerisourceBergen Drug Corp for the supply of Jemperli (venetoclax) 500 mg/10 ml vials, with an ultimate completion date of December 29, 2025. The contract was competitively awarded without set-aside designation under a firm fixed-price delivery order mechanism. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office location. This delivery order is a...
- The Defense Logistics Agency has awarded a delivery order valued at $7,451.89 to AmerisourceBergen Drug Corp for the supply of Jemperli 500 mg/10 mL vials. This is a firm fixed-price, competitively awarded contract with no set-aside designation, due for completion by August 11, 2025. The awardee, headquartered in Conshohocken, Pennsylvania, will perform delivery from its corporate office location. This delivery order is issued under AmerisourceBergen Drug Corp's larger Indefinite Delivery...
- The Defense Logistics Agency (DLA) awarded a firm fixed price delivery order valued at $113,363.90 to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, for the supply of JEMPERLI 500 MG/10 ML VIAL 10ML pharmaceutical products. This delivery order is part of a larger indefinite delivery contract (IDC) awarded solely to Amerisourcebergen Drug Corp, with a potential value of $999,999,999.00 and a performance period through December 31, 2025. The IDC serves as the primary...
- AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, was awarded a delivery order valued at $14,903.78 on April 24, 2025, for the supply of JEMPERLI 500 mg/10 ml vials. This competitive, non-set-aside contract utilizes firm fixed pricing and is scheduled for completion by May 15, 2025. The award is funded by the Department of Defense through its Medical Supply Chain organization and represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract...
- This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $22,355.67 contract is for the supply of JEMPERLI 500 MG/10 ML VIAL 10ML, a pharmaceutical product. The award is not set aside and has an ultimate completion date of July 7, 2025. AmerisourceBergen Drug Corp holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical,...
- The Defense Logistics Agency awarded a $6,992 delivery order to Amerisourcebergen Drug Corporation for 500 mg/10 ml vials of Jemperli. The firm fixed price order is being fulfilled from Amerisourcebergen's Conshohocken, Pennsylvania location to support the Defense Logistics Agency's medical product needs. No additional details were provided regarding the original solicitation or whether this delivery order was placed against an existing indefinite-delivery/indefinite-quantity contract vehicle....
- This contract was awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, to supply the pharmaceutical product JEMPERLI 500 MG/10 ML VIAL 10ML. The firm fixed-price delivery order, valued at $34,009.17, has a completion date of January 26, 2024. Amerisourcebergen Drug Corp is a prime contractor that has received numerous federal contracts from the DLA to provide pharmaceuticals, medical supplies, and distribution services in...
- This is a $29,434.36 firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) Troop Support Medical to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The contract is for the supply of 4566810727 JEMPERLI 500 MG/10 ML VIAL 10ML, with a performance period ending on January 22, 2025. This award is not designated as a set-aside contract. The contract is issued under AmerisourceBergen's $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support...
- This is a firm fixed price delivery order awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of the global pharmaceutical distributor Amerisourcebergen Corporation. The $13,984.10 contract is for the delivery of 4563188691 JEMPERLI 500 MG/10 ML VIAL 10ML pharmaceutical products, with a completion date of January 19, 2024. Amerisourcebergen Drug Corp has previously received numerous federal contract awards to supply pharmaceuticals, medical supplies, and...
- The Defense Logistics Agency awarded a delivery order valued at $2,098.25 to AmerisourceBergen Drug Corp for VENCLEXTA Starting Pack UD UU 42S, a pharmaceutical product for federal medical procurement. This firm fixed-price delivery order, issued on September 26, 2025, with an ultimate completion date of October 20, 2025, represents a non-set-aside competitive award to the Conshohocken, Pennsylvania-based pharmaceutical distributor. The delivery order is issued under AmerisourceBergen's larger...
- SPE2DB20D3103Indefinite Delivery Contract
- SPE2DB20D3103-SPE2DB25FP5N2Delivery Order
The Defense Logistics Agency awarded a delivery order valued at $89,422.68 to AmerisourceBergen Drug Corp for Jemperli (venetoclax) 500 mg/10 mL vials on July 17, 2025, with completion expected by August 7, 2025. This firm fixed-price delivery order, issued without set-aside designation, leverages AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (contract SPE2DX), valued at $999,999,999 through December 2026. The place of performance is AmerisourceBergen's Corporate Office location in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and critical vendor for federal medical procurement, supplies a comprehensive range of medications and medical supplies to support military and veteran healthcare systems through the DLA's Medical Supply Chain. As a prime contractor under the SPE2DX global pharmaceutical support vehicle, the company fulfills delivery orders for specialty medications, brand-name and generic drugs, vaccines, and related medical commodities across multiple therapeutic domains to support Defense Health Agency operations and other federal healthcare systems. This competitively awarded delivery order reflects the company's established capability to meet federal pharmaceutical procurement requirements on an open competition basis.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $89.4k | 7/17/25 |